doi: 10.1111/j.1365-2125.1989.tb03458.x.
Interaction between vigabatrin and phenytoin
Affiliations
- PMID:2757906
- PMCID: PMC1379676
- DOI: 10.1111/j.1365-2125.1989.tb03458.x
Item in Clipboard
Interaction between vigabatrin and phenytoin
E M Rimmer et al. Br J Clin Pharmacol.1989.
Display options
Format
Display options
Format
Abstract
1. The study was designed to determine the mechanism by which vigabatrin causes a fall in plasma phenytoin concentrations when added to the drug therapy of eight epileptic patients. 2. Total plasma phenytoin concentration was measured before and at intervals during 5 weeks' treatment with vigabatrin. 3. Plasma protein binding of phenytoin, the urinary ratio of phenytoin to 5-(p-hydroxyphenyl)-5-phenylhydantoin, and antipyrine clearance were measured before and at the end of treatment period. 4. Mean plasma phenytoin concentration fell significantly by 23% during the fifth week. 5. No change was found in any of the other measures. 6. Although an interaction between phenytoin and vigabatrin has been confirmed, the mechanism has not been elucidated.
Similar articles
- Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability.Gatti G, Bartoli A, Marchiselli R, Michelucci R, Tassinari CA, Pisani F, Zaccara G, Timmings P, Richens A, Perucca E.Gatti G, et al.Br J Clin Pharmacol. 1993 Dec;36(6):603-6. doi: 10.1111/j.1365-2125.1993.tb00422.x.Br J Clin Pharmacol. 1993.PMID:12959280Free PMC article.
- Double-blind study of vigabatrin in the treatment of drug-resistant epilepsy.Tassinari CA, Michelucci R, Ambrosetto G, Salvi F.Tassinari CA, et al.Arch Neurol. 1987 Sep;44(9):907-10. doi: 10.1001/archneur.1987.00520210009010.Arch Neurol. 1987.PMID:2887152Clinical Trial.
- Vigabatrin. Clinical pharmacokinetics.Rey E, Pons G, Olive G.Rey E, et al.Clin Pharmacokinet. 1992 Oct;23(4):267-78. doi: 10.2165/00003088-199223040-00003.Clin Pharmacokinet. 1992.PMID:1395360Review.
- A multicentre study of vigabatrin for drug-resistant epilepsy.Browne TR, Mattson RH, Penry JK, Smith DB, Treiman DM, Wilder BJ, Ben-Menachem E, Miketta RM, Sherry KM, Szabo GK.Browne TR, et al.Br J Clin Pharmacol. 1989;27 Suppl 1(Suppl 1):95S-100S. doi: 10.1111/j.1365-2125.1989.tb03468.x.Br J Clin Pharmacol. 1989.PMID:2667606Free PMC article.Clinical Trial.
- Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures.Fischer JH, Patel TV, Fischer PA.Fischer JH, et al.Clin Pharmacokinet. 2003;42(1):33-58. doi: 10.2165/00003088-200342010-00002.Clin Pharmacokinet. 2003.PMID:12489978Review.
Cited by
- Vigabatrin.Wheless JW, Ramsay RE, Collins SD.Wheless JW, et al.Neurotherapeutics. 2007 Jan;4(1):163-72. doi: 10.1016/j.nurt.2006.11.008.Neurotherapeutics. 2007.PMID:17199033Free PMC article.Review.
- New antiepileptic drugs: lacosamide, rufinamide, and vigabatrin.Strom LA, Koh S, Frey L.Strom LA, et al.Curr Treat Options Neurol. 2010 Jul;12(4):287-99. doi: 10.1007/s11940-010-0079-4.Curr Treat Options Neurol. 2010.PMID:20842588
- Newer anticonvulsants: comparative review of drug interactions and adverse effects.Sabers A, Gram L.Sabers A, et al.Drugs. 2000 Jul;60(1):23-33. doi: 10.2165/00003495-200060010-00003.Drugs. 2000.PMID:10929928Review.
- Single-blind, placebo-controlled multicenter trial of vigabatrin in the treatment of epilepsy. The Italian Study Group on Vigabatrin.[No authors listed][No authors listed]Ital J Neurol Sci. 1992 Dec;13(9):741-7. doi: 10.1007/BF02229159.Ital J Neurol Sci. 1992.PMID:1483856Clinical Trial.
- Effect of vigabatrin and gabapentin on phynytoin pharmacokinetics in the dog.Matar KM, Nicholls PJ, Tekle A, Bawazir SA, al-Hassan MI.Matar KM, et al.Eur J Drug Metab Pharmacokinet. 2000 Jul-Dec;25(3-4):189-93. doi: 10.1007/BF03192312.Eur J Drug Metab Pharmacokinet. 2000.PMID:11420888
References
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources